Alnylam Pharmaceuticals · 1 week ago
Vice President, Target Discovery, Validation, and Human Genetics
Cambridge, MA
Full-time
Onsite
Director/Executive
$310K/yr - $420K/yr
15+ years expAlnylam Pharmaceuticals is a leader in RNAi therapeutics, seeking a visionary scientific leader to serve as Vice President of Target Discovery, Validation, and Human Genetics. This role involves leading teams to identify and validate novel therapeutic targets, integrating human genetics with biological expertise, and ensuring the organization excels in genetically informed drug discovery.
BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Hiring Manager
Jill Donovan
Responsibilities
Define and execute an enterprise-level strategy for target discovery and validation, integrating human genetics and experimental biology to fuel Alnylam’s RNAi pipeline
Lead and develop the Human Genetics and Discovery & Validation Biology teams, ensuring scientific excellence, clear prioritization, and sustained target delivery (>10 targets per year)
Establish Alnylam as an industry leader in the application of large-scale human genetic data for drug target identification and prioritization
Oversee generation of rigorous, decision-enabling data packages to support target nomination and progression through governance forums
Partner cross-functionally with Research, Development, Commercial, and Finance to align discovery priorities with portfolio strategy and investment decisions
Identify, evaluate, and champion opportunities to expand Alnylam’s access to genetic datasets, technologies, and external collaborations
Represent the discovery portfolio internally and externally, building credibility with senior leadership, partners, and the broader scientific community
Qualification
Required
PhD in human genetics, statistical genetics, molecular biology, or a related discipline, with deep scientific credibility in genetically driven drug discovery
15+ years of progressive experience in biopharmaceutical research, including senior leadership roles with accountability for strategy, teams, and portfolio outcomes
Internationally recognized expert in human genetics–enabled target discovery, with a strong record of high-impact publications, target nominations, and/or pipeline contributions
Demonstrated ability to lead and integrate large, multidisciplinary teams spanning computational genetics, in vitro biology, and in vivo disease models
Proven track record of shaping discovery strategy and influencing portfolio-level investment decisions at the enterprise level
Strong business and matrix leadership skills, with experience partnering effectively across research, development, commercial, and corporate functions
Exceptional communication and executive presence, with the ability to articulate complex scientific concepts to diverse internal and external stakeholders
Benefits
Comprehensive benefits including medical, dental, and vision coverage
Life and disability insurance
A lifestyle reimbursement program
Flexible spending and health savings accounts
A 401(k) with a generous company match
Paid time off
Wellness days
Holidays
Two company-wide recharge breaks
Generous family resources and leave
Company
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
1001-5000 employees
H1B Sponsorship
Alnylam Pharmaceuticals has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2022 (18)
2021 (19)
2020 (7)
Funding
Current Stage
Public CompanyTotal Funding
$4.55BKey Investors
Blackstone Life SciencesBlackstone CreditRegeneron
2025-09-09Post Ipo Debt· $661.25M
2022-09-12Post Ipo Debt· $900M
2022-03-04IPO
Leadership Team
Yvonne Greenstreet
Chief Executive Officer
Jeff Poulton
Chief Financial Officer
Recent News
Clinical Trials Arena
2026-01-16
Longevity.Technology
2026-01-14
2026-01-13
Company data provided by crunchbase